US Patent

US8795741 — Methods for treating patients who are candidates for inhaled nitric oxide treatment

Method of Use · Assigned to INO Therapeutics LLC · Expires 2029-06-30 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for reducing the risk of pulmonary edema in patients undergoing inhaled nitric oxide treatment.

USPTO Abstract

Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in the patient, leading to pulmonary edema.

Drugs covered by this patent

Inomax (NITRIC OXIDE) · Vero Biotech Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1286`	—	Inomax
`U-1286`	—	Inomax

Patent Metadata

Patent number: US8795741
Jurisdiction: US
Classification: Method of Use
Expires: 2029-06-30
Drug substance claim: No
Drug product claim: No
Assignee: INO Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.